Skip to main content

Table 12 Expression levels of miRNAs targeting i.a. TYMS mRNA in cancer

From: MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy

miRNA Level Cancers References
miR-375-3p Down CRC tissues, Caco2, HCT116, SW480, HT29 cell lines Xu et al. (2020b)
  Down CRC tissues Liu et al. (2020a)
  Down CRC tissues: 5FU-resistant vs sensitive Chen et al. (2020b)
  Down CRC tissues, Caco2, HCT116, SW480, HT29, SW620 lines Xu et al. (2019a)
  Down HCT8/FU (5FU resistant) vs HCT8 (parental sensitive) Xu et al. (2019a)
  Down HCT116/FU (5FU resistant) vs HCT116 (sensitive) Xu et al. (2019a)
  Down CRC tissues: 5FU-resistant vs sensitive Xu et al. (2019a)
  Down in serum of CRC patients Huang et al. (2020a)
  Down CRC tissues, HCT116, SW480, HT29, SW620 cell lines Xu et al. (2016a)
  Down CRC tissues, SW480, HT29, SW620, HCT116, HCT8 Mao et al. (2016)
  Down CRC stage III–IV vs stage I–II Mao et al. (2016)
  Down CRC tissues Wang et al. (2014b)
  Down CRC tissues, HT29, SW620, HCT116 cell lines Dai et al. (2012)
  Down GC tissues and three cell lines Liu et al. (2019b)
  Down GC tissues and two cell lines Huang et al. (2019b)
  Down GC tissues and ten cell lines Kang et al. (2018)
  Down GC tissues Chen et al. (2017d)
  Down GC tissues Yuan et al. (2018)
  Down ESCC tissues and four cell lines Li et al. (2021a)
  Down ESCC tissues Cheng et al. (2020b)
  Down ESCC tissues and two cell lines Xu et al. (2019b)
  Down ESCC tissues and one cell line Hu et al. (2017b)
  Down ESCC tissues and cell lines Kong et al. (2012)
  Down LSCC and three cell lines Chang et al. (2020)
  Up LSCC: III/IV vs I/II TNM stage Wu et al. (2016)
  Down LSCC: III–IV vs I–II clinical stage Guo et al. (2016)
  Down LSCC tissues and two cell lines Wang et al. (2016b)
  Down LSCC tissues, UICC advanced III–IV vs early I–II stage Luo et al. (2014)
  Down OSCC tissues and four cell lines Tong et al. (2021)
  Down OSCC tissues and four cell lines Wu et al. (2017)
  Down OSCC tissues, with vs without lymph node metastasis Zhang et al. (2017)
  Down OSCC tissues Shi et al. (2015)
  Down NSCLC tissues and A549, H1299 cell lines Jin et al. (2021)
  Down NSCLC tissues, stages IV vs III vs II vs I Chen et al. (2017f)
  Down NSCLC (SqCLC) tissues, stage III vs II Chen et al. (2017g)
  Up BRCA tissues (luminal A/B, HER2+), three cell lines Guan et al. (2021)
  Down HCC tissues and four cell lines (i.a. Huh7) Xu et al. (2021)
  Down HCC tissues and five cell lines Li et al. (2021b)
  Down HCC tissues and four cell lines (i.a. Huh7) Li et al. (2021c)
  Down HCC tissues and five cell lines (i.a. Huh7) Li et al. (2018b)
  Down HCC tissues He et al. (2012)
  Down HCC tissues Liu et al. (2010)
  Down PDAC tissues and two cell lines (PANC-1, SW 1990) Yonemori et al. (2017)
  Up PDAC tissues and ten cell lines (i.a. PANC-1, SW 1990) Yang et al. (2016)
  Down PDAC tissues Zhou et al. (2014b)
  Down PDAC tissues Song et al. (2013a)
  Down PDAC tissues and four cell lines (i.a. PANC-1, SW 1990) Song et al. (2013b)
  Down CeCa tissues (stage I-IV) and four cell lines Cao et al. (2021)
  Up CeCa: PTX-resistant vs pre-chemotherapy tissues Shen et al. (2013)
  Down CeCa tissues, FIGO stage IIA vs IB1/IB2 Wang et al. (2011)
  Down OVCA tissues and four cell lines Shu et al. (2021)
  Up PCa tissues Porzycki et al. (2018)
  1. ,For description see footnote to Table 2